University of Maryland (UM) Ventures and Glycocept, Inc. announced today that the University of Maryland, Baltimore (UMB) has granted Glycocept worldwide, exclusive licensing rights to a UMB patent and technology to modify monoclonal antibodies to alter their effector functions. Eric J. Sundberg, Ph.D., Associate Professor of Medicine at the University of Maryland School of Medicine (UMSOM), and Co-Director, Division of Basic Science, Institute of Human Virology (IHV), and Beatriz Trastoy, Ph.D., post-doctoral fellow at Dr. Sundberg’s laboratory at the IHV/UMSOM are the patent inventors. Biopharmaceutical industry veteran Ronald P. Dudek, who most recently served as Vice President of Commercial Strategy at Juno Therapeutics, Inc., is Glycocept’s President and Chief Executive Officer.